Reports Q4 revenue $12M, consensus $8.93M. “2024 was a transformational year for Zevra. We emerged as a commercial stage company and are executing on the opportunity to positively impact the lives of people living with rare diseases,” said Neil F. McFarlane, Zevra’s president and CEO. “We are starting 2025 from a position of strength. Our priorities are guided by Zevra’s strategic plan, unveiled during our third quarter call and categorized under four actionable pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strategic Growth and Financial Strength Drive Buy Rating
- Zevra Therapeutics launches new disease state awareness campaign
- Zevra Therapeutics Sells Priority Review Voucher for $150M
- Zevra Therapeutics to sell Rare Pediatric Disease PRV for $150M
- ZVRA Earnings this Week: How Will it Perform?
Questions or Comments about the article? Write to editor@tipranks.com